BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 11911407)

  • 1. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies.
    Zhao WL; Chen SJ; Shen Y; Xu L; Cai X; Chen GQ; Shen ZX; Chen Z; Wang ZY
    Leuk Lymphoma; 2001; 42(6):1265-73. PubMed ID: 11911407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY; Yang CH; Chen YC
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
    Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide, a therapeutic agent for APL.
    Zhang TD; Chen GQ; Wang ZG; Wang ZY; Chen SJ; Chen Z
    Oncogene; 2001 Oct; 20(49):7146-53. PubMed ID: 11704843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
    Shen ZX; Chen GQ; Ni JH; Li XS; Xiong SM; Qiu QY; Zhu J; Tang W; Sun GL; Yang KQ; Chen Y; Zhou L; Fang ZW; Wang YT; Ma J; Zhang P; Zhang TD; Chen SJ; Chen Z; Wang ZY
    Blood; 1997 May; 89(9):3354-60. PubMed ID: 9129042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
    J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
    Niu C; Yan H; Yu T; Sun HP; Liu JX; Li XS; Wu W; Zhang FQ; Chen Y; Zhou L; Li JM; Zeng XY; Yang RR; Yuan MM; Ren MY; Gu FY; Cao Q; Gu BW; Su XY; Chen GQ; Xiong SM; Zhang TD; Waxman S; Wang ZY; Chen Z; Hu J; Shen ZX; Chen SJ
    Blood; 1999 Nov; 94(10):3315-24. PubMed ID: 10552940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
    Cai X; Shen YL; Zhu Q; Jia PM; Yu Y; Zhou L; Huang Y; Zhang JW; Xiong SM; Chen SJ; Wang ZY; Chen Z; Chen GQ
    Leukemia; 2000 Feb; 14(2):262-70. PubMed ID: 10673743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
    Chen GQ; Shi XG; Tang W; Xiong SM; Zhu J; Cai X; Han ZG; Ni JH; Shi GY; Jia PM; Liu MM; He KL; Niu C; Ma J; Zhang P; Zhang TD; Paul P; Naoe T; Kitamura K; Miller W; Waxman S; Wang ZY; de The H; Chen SJ; Chen Z
    Blood; 1997 May; 89(9):3345-53. PubMed ID: 9129041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
    Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
    Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia.
    Wang ZY; Chen Z
    Lancet Oncol; 2000 Oct; 1():101-6. PubMed ID: 11905660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
    Chou WC; Dang CV
    Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
    Rojewski MT; Körper S; Schrezenmeier H
    Leuk Lymphoma; 2004 Dec; 45(12):2387-401. PubMed ID: 15621751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis.
    Chen Z; Wang ZY; Chen SJ
    Pharmacol Ther; 1997; 76(1-3):141-9. PubMed ID: 9535176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
    Chen GQ; Zhu J; Shi XG; Ni JH; Zhong HJ; Si GY; Jin XL; Tang W; Li XS; Xong SM; Shen ZX; Sun GL; Ma J; Zhang P; Zhang TD; Gazin C; Naoe T; Chen SJ; Wang ZY; Chen Z
    Blood; 1996 Aug; 88(3):1052-61. PubMed ID: 8704214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
    Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
    Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
    Jing Y
    Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
    Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
    Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide: acute promyelocytic leukemia and beyond.
    Bachleitner-Hofmann T; Kees M; Gisslinger H
    Leuk Lymphoma; 2002 Aug; 43(8):1535-40. PubMed ID: 12400595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
    Sternsdorf T; Puccetti E; Jensen K; Hoelzer D; Will H; Ottmann OG; Ruthardt M
    Mol Cell Biol; 1999 Jul; 19(7):5170-8. PubMed ID: 10373566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.